Draft FDA guidance on the difference between "wellness" and "medical" devices will slow adoption of wearables by biopharma in the near term, according to an analyst. Juniper Research analyst James Moar told Outsourcing-Pharma the placing of limits on the types of information that can have medical uses will slow uptake. Article